(PRFX) – Management Comments
-
PainReform (PRFX) Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy
-
PainReform (PRFX) Issues Year-End Business Update, Remains on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in H2 2022
Back to PRFX Stock Lookup